Clara Mariette

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Vincent Ribrag, Serge Koscielny, Jacques Bosq et al. · The Lancet · 2016 · 186 citations

Lymphoid Neoplasia, Surgical Oncology, Medicine +4

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

Nico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli et al. · Haematologica · 2018 · 109 citations · Full text

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Xavier Leleu, Cyrille Hulin, Jérôme Lambert et al. · Nature Medicine · 2024 · 87 citations · Full text

Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus

Raphaële Germi, Clara Mariette, Sophie Alain et al. · Antiviral Research · 2013 · 70 citations

Transplantation, Transplant Recipients, Immunology +6